Abstract
The Center for Medical Technology Policy and the Molecular Evidence Development Consortium gathered a diverse group of more than 50 stakeholders to develop consensus on a core set of data elements and values essential to understanding the clinical utility of molecularly targeted therapies in oncology. The Center for Medical Technology Policy and the Molecular Evidence Development Consortium gathered a diverse group of more than 50 stakeholders to develop consensus on a core set of data elements and values essential to understanding the clinical utility of molecularly targeted therapies in oncology.
Original language | English (US) |
---|---|
Pages (from-to) | 982-986 |
Number of pages | 5 |
Journal | Cell |
Volume | 171 |
Issue number | 5 |
DOIs |
|
State | Published - Nov 16 2017 |
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology